Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, People's Republic of China.
Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, People's Republic of China.
Bioorg Med Chem. 2021 Jun 15;40:116192. doi: 10.1016/j.bmc.2021.116192. Epub 2021 May 1.
On the basis of our earlier discovered natural product penipyridone G with potential lipid-lowering utility, 35 penipyridone derivatives were designed, synthesized and characterized. Based on the oleic acid-induced HepG2 cell lipid accumulation model, compounds 12c, 14, 15f, 15k, 15o, 15p and 16f showed potent lipid-lowering activities among the synthetic compounds at 10 μM. In particular, compounds 4, 15k, 15o showed significant activities on inhibiting lipid accumulation in insulin resistant HepG2 cells, and these three compounds were safe and non-toxic within the concentration range of 400 μM. In comparison, 15o possessed the best lipid-lowering activity. Compared with the vehicle group, the triglyceride inhibition rate of 15o was about 30.2%, and the total cholesterol inhibition rate was about 14.8% at 20 μM, which was equipotent to Simvastatin. Our research indicates that 15o may serve as a promising lead compound for the development of hypolipidemic drugs.
基于我们之前发现的具有潜在降脂作用的天然产物 penipyridone G,设计、合成并表征了 35 种 penipyridone 衍生物。基于油酸诱导的 HepG2 细胞脂质积累模型,在合成化合物中,化合物 12c、14、15f、15k、15o、15p 和 16f 在 10 μM 时表现出很强的降脂活性。特别是化合物 4、15k 和 15o 在抑制胰岛素抵抗 HepG2 细胞脂质积累方面表现出显著的活性,这三种化合物在 400 μM 的浓度范围内安全无毒。相比之下,15o 具有最佳的降脂活性。与载体组相比,15o 在 20 μM 时的甘油三酯抑制率约为 30.2%,总胆固醇抑制率约为 14.8%,与辛伐他汀相当。我们的研究表明,15o 可能是开发降脂药物的有前途的先导化合物。